Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: Postmarketing surveillance in Japan

Clinical presentation of Legionella pneumonia: Evaluation of clinical scoring systems and therapeutic efficacy

“…Based on the several clinical studies [17e21], macrolides and quinolones, . In a post-marketing surveillance study, garenoxacin showed an efficacy rate of greater than 90% for both atypical and bacterial pneumonia [26,27]. In this study, we confirmed the good clinical efficacy of quinolones, including pazufloxacin and garenoxacin against Legionella pneumonia.…”

Mycoplasma pneumoniae from the Respiratory Tract and Beyond

“…Similar findings were described in a study by Morozumi et al (391), in which 19 of 53 (35.8%) patients with macrolide-resistant infections had macrolide treatment changed to levofloxacin or minocycline, versus only 4/58 (6.9%) of children with susceptible isolates. Other quinolones such as garenoxacin, which is active in vitro and in vivo against M. pneumoniae, are sometimes used in Japan (407,408). Although there are no data concerning the clinical efficacy of garenoxacin against MRMP, there is no reason to believe it should not be effective, as there is no cross-resistance of quinolones with macrolides.…”

In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan

“…Garenoxacin and pazufloxacin are quinolone antimicrobial agents, which have been marketed only in Japan. Garenoxacin is des-F(6)-quinolone that lacks the fluorine atom found at the 6position in other fluoroquinolones, and it showed high clinical efficacy against CAP [24,25]. These quinolones have broad and potent antibacterial activity against respiratory pathogens including Legionella spp.…”